Ric M. Procyshyn, BScPharm, MSc, PharmD, PhD(A,
B)
Katelyn Halpape, BSP, ACPR, PharmD, BCPP(C)
David D. Kim,
BSc, MSc, PhD(D)
The Editors wish to acknowledge contributions from the following chapter
co-editors:
Kaitlyn Baldwin, PharmD, ACPR(E) (Unapproved Treatments)
Alasdair M. Barr, PhD(B, F) (Drugs of Abuse)
Andrius Baskys, MD, PhD(G) (Drugs for Treatment of Dementia, Pharmacogenetic
Information for Common Psychotropic Drugs)
Vincent Dagenais-Beaulé, MSc, PharmD(H) (Antipsychotics)
Lynda Eccott, BSc, MScPharm(I) (Natural Health Products)
Dean Elbe, BScPharm, PharmD, BCPP(J) (Drugs for ADHD)
Brooke Gessner, PharmD, ACPR(C) (Unapproved Treatments)
Katelyn Halpape, BSP, ACPR, PharmD, BCPP(C) (Mood Stabilizers)
Rahim Janmohamed, BScPharm(K) (Treatment of Substance Use Disorders)
David D. Kim, BSc, MSc, PhD(D) (Antipsychotic-Induced Extrapyramidal Side Effects and Their Management, Drugs of Abuse)
Melanie McLeod, BSP, ACPR, PharmD, BCPP(L) (Antidepressants)
Ric M. Procyshyn, BScPharm, MSc, PharmD, PhD(A, B) (Antipsychotics, Sex-Drive Depressants)
Reza Rafizadeh, BScPharm, ACPR, PhD(M) (Treatment of Substance Use Disorders)
Christian G. Schütz, MD, PhD, MPH, FRCPC(L) (Treatment of Substance Use Disorders)
Amy Soubolsky, BSP, MScPharm(C, N) (Mood Stabilizers)
Anca Toma, MD(A) (Bright Light Therapy)
Fidel Vila-Rodriguez, MD, PhD, FRCPC, DFAPA(O, P) (Electroconvulsive Therapy, Repetitive
Transcranial Magnetic Stimulation)
Bree Zehm, PharmD(Q) (Antidepressants)
Tony Zhou, PharmD, ACPR(R) (Anxiolytics, Hypnotics/Sedatives)
(A) Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
(B) British Columbia Mental Health & Substance Use Services Research Institute, Vancouver, BC, Canada
(C) College of Pharmacy and Nutrition, University of Saskatchewan, Saskatoon, SK, Canada
(D) Department of Psychiatry and Psychotherapy, TUM School of Medicine and Health, Technical University of Munich, Germany
(E) Lower Mainland Pharmacy Services and Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
(F) Department of Anesthesiology, Pharmacology & Therapeutics, University of British Columbia, Vancouver, BC, Canada
(G) Specialty Center, WesternU Health, Western University of Health Sciences, Pomona, CA, USA
(H) Department of Clinical Pharmacy, Jewish General Hospital, Lady Davis Institute for Medical Research, Montreal, QC, Canada
(I) Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, BC, Canada
(J) Healthy Minds Centre, BC Children's Hospital, Vancouver, BC, Canada
(K) British Columbia Centre on Substance Use, Interdisciplinary Addiction Fellowship Program, Vancouver, BC, Canada
(L) Department of Psychiatry, Saskatchewan Health Authority, Regina, SK, Canada
(M) BC Mental Health and Substance Use Services, Provincial Health Service Authority, Vancouver, BC, Canada
(N) Saskatchewan Health Authority, Saskatoon, SK, Canada
(O) Non-Invasive Neurostimulation Therapies Laboratory, Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada
(P) School of Biomedical Engineering, University of British Columbia, Vancouver, BC, Canada
(Q) Department of Pharmacy, Island Health, Victoria, BC, Canada
(R) Community Mental Health & Substance Use, Fraser Health Authority, Lower Mainland Pharmacy Services, Vancouver, BC, Canada